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Postpartum haemorrhage (PPH) is a major cause of maternal morbidity and mortality and its 68 
incidence is increasing in many countries despite comprehensive management guidelines. A national 69 
quality improvement programme called the Obstetric Bleeding Strategy for Wales (OBS Cymru) was 70 
introduced in all obstetric units in Wales. The aim was to reduced moderate bleeds (1000 mL) 71 
progressing to massive haemorrhage (2500 mL or more) and the need for red blood cell transfusion.  72 
Methods 73 
A PPH care bundle was introduced into all 12 obstetric units in Wales and included all women giving 74 
birth in 2017 and 2018 (n=61094).  The care bundle consisting of: universal risk assessment, 75 
quantitative measurement of blood loss after all deliveries (as opposed to visual estimation), 76 
structured escalation to senior clinicians and point-of-care viscoelastometric-guided early fibrinogen 77 
replacement. Data were collected at each obstetric unit and submitted to a national database. The 78 
main outcome measures were incidence of massive PPH, defined as bleeds of 2500 mL or more and 79 
red blood cell transfusion.  80 
Results 81 
There was good uptake of the intervention with use of quantitative blood loss measurement 82 
increasing to 98.1% of all maternities. Massive haemorrhage decreased by 1.10 (95% CI 0.28 to 1.92) 83 
per 1000 maternities per year (P=0.011). Fewer women progressed from moderate bleeds to 84 
massive haemorrhage in the last 6 months, 74/1490 (5.0%), than in the first 6 months, 97/1386 85 
(7.0%), (P=0.021). Units of red blood cells transfused decreased by 7.4 (95% CI 1.6 to 13.2) per 1000 86 
maternities per year (P=0.015). Red blood cells were transfused to 350/15204 (2.3%) and 268/15150 87 
(1.8%) (P=0.001) in the first and last 6 months, respectively. There was no increase in the number of 88 















women with lowest haemoglobin below 80 g/L during this time period. Infusions of fresh frozen 89 
plasma fell and there was no increase in the number of women with haemostatic impairment.  90 
Conclusions 91 
The OBS Cymru care bundle was feasible to implement and associated with progressive, clinically 92 
significant improvements in outcomes for PPH across Wales. It is applicable across obstetric units of 93 
widely varying size, complexity and staff mixes.  94 
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 98 
Introduction 99 
Bleeding after childbirth (postpartum haemorrhage, PPH) is the leading cause of maternal death 100 
worldwide.1 In resource rich countries PPH causes 80% of severe maternal morbidity and its 101 
incidence is increasing in many regions,2 3 including Wales,4 despite international guidance.5-7 In the 102 
UK PPH is described as moderate at 1000 mL blood loss and severe at 2000 mL.6 Massive PPH is 103 
defined as 2500 mL or more and, in resource rich countries, is associated with a hysterectomy rate 104 
of 6% and intensive care admission in 11.8% of cases.3 Post-traumatic stress disorder is common 105 
after PPH.8 Multi-professional management of PPH requires the skills of midwives, obstetricians, 106 
anaesthetists, healthcare support staff and haematologists working in an effective team. Variations 107 
in care are widely reported, with delays in escalation to senior staff a common theme.9 10 A recent 108 
confidential enquiry identified deficiencies in care, compared to guidelines, in 90% of cases.11 109 
Bleeding after childbirth may be exacerbated by haemostatic impairment. A Clauss fibrinogen below 110 
2 g/L is associated with progression of bleeding,12 13 although clinically significant deficiencies of 111 















other clotting factors and platelets are less common.14-16 In severe PPH, laboratory coagulation 112 
results are often too slow to be useful clinically and guidelines recommend the use of empirical 113 
treatment with fixed ratios of red blood cells (RBC), fresh frozen plasma (FFP) and platelets, based 114 
on data derived from major trauma5 6. This results in many women receiving blood components 115 
when haemostasis is normal.17  Point-of-care haemostasis test results, using viscoelastometry, are 116 
available within 10 minutes and can direct timely and targeted replacement of fibrinogen and avoid 117 
unnecessary FFP during PPH.15 18-20 118 
International PPH quality improvement projects have been undertaken with the aim of standardising 119 
care and improving outcomes. Interventions have included risk assessment, quantitative 120 
measurement of blood loss and escalation to senior clinicians, although to date all have used 121 
empirical, fixed-ratio transfusion therapy.21-24 OBS Cymru is a national quality improvement project 122 
developed by combining lessons learnt during 10-years of research17 with themes emerging from 123 
international PPH quality improvement projects.21-24 OBS Cymru introduced an integrated care 124 
bundle into all obstetric units in Wales.25 A key and unique feature was the inclusion of 125 
viscoelastometric point-of-care haemostatic tests to guide targeted blood component 126 




Launched in November 2016, OBS Cymru introduced a PPH care bundle between January and April 131 
2017 into all 12 obstetric units in Wales. These obstetric units support between 500 and 6000 births 132 
per year, with about 31,000 births across Wales. The lead research and development office 133 
designated OBS Cymru as a quality improvement project and service evaluation according to NHS 134 















guidance. Consequently ethical approval and individual consent to collect and report data was not 135 
required.  136 
Patient and public representatives had provided feedback through local focus groups regarding 137 
important outcomes and priorities throughout the programme of research that underpinned OBS 138 
Cymru.17 A James Lind Alliance partnership into bleeding disorders in 2018 had ranked research in 139 
the field as the highest priority.26 Two additional women, representing patients and the public, sat 140 
on the OBS Cymru steering committee from its inception and were involved in the design and 141 
conduct of the project throughout.  142 
The design, initiation and project interventions have been described in detail previously.25 OBS 143 
Cymru funding provided a Rotem Sigma point-of-care coagulation device (Instrumentation 144 
Laboratories, Werfen, Barcelona, Spain) for use in each obstetric unit. The intervention promoted: 145 
1. Risk assessment of all mothers admitted to delivery suite. 146 
2. Quantitative measurement of blood loss from delivery using volumetric and gravimetric 147 
techniques for all births as opposed to visual estimation. Details of the method and 148 
validation data supporting quantitative measurement have been published. 4 25 27 149 
3. Escalation of care to senior clinicians, if not already involved, at specified volumes of blood 150 
loss. At the latest, a senior midwife was informed at 500 mL, an obstetrician and 151 
anaesthetist were required to attend the mother at 1000 mL and a consultant obstetrician 152 
and anaesthetist informed at 1500 mL. 153 
4. Point-of-care tests of haemostasis were taken at 1000 mL or earlier for clinical concern. If 154 
required, targeted, early replacement of fibrinogen was administered. The algorithm and 155 
recommended dose of fibrinogen or FFP is shown in supplementary material figure 1. 156 
Tranexamic acid was infused as soon as abnormal bleeding was recognised and repeated if 157 
bleeding continued.28  158 














The intervention was intended for all births and was not limited to those complicated by abnormal 159 
bleeding. It was underpinned by a standardised paperwork proforma that prompted management 160 
and created a contemporaneous record of findings and actions.29 An all Wales guideline reinforced 161 
the intervention and standardised obstetric management.30 Antenatal anaemia, cell salvage and 162 
transfusion policies were unchanged throughout the project. 163 
The Rotem point-of-care coagulation devices were supported by a validated algorithm15 17 18 29 and 164 
were compliant with internal and external quality assurance. A minor revision of the Rotem 165 
interpretation algorithm was introduced in 2018 to emphasise the importance of correcting 166 
hypofibrinogenaemia before considering FFP (supplementary material figure 1).29 Haemostatic 167 
impairment was defined as fibrinogen <2 g/L, Fibtem A5 <12 mm or PT or aPTT >1.5 times normal6 31 168 
(equating to PT >16 or aPTT >50 secs). In autumn 2018 all Rotem devices received a hardware 169 
update which was associated with slightly lower Fibtem A5 measurements, the blood product 170 
algorthim was not adjusted. 171 
The national team co-ordinated multi-professional training at each unit, as described,25 this training 172 
was front-loaded at the start of the project with top-up training throughout the 2 year period. A lead 173 
midwife, obstetrician, anaesthetist and haematologist were appointed at each site to support 174 
ongoing training and oversee the project locally with the midwifery time funded by the project. The 175 
intervention was introduced during the first 6 month period (January to June 2017) and adopted 176 
progressively by obstetric units throughout 2017 and 2018. Training covered quantitative 177 
measurement of blood loss, escalation of care and interpretation of Rotem results. The OBS Cymru 178 
principles were integrated into PROMPT (PRactical Obstetric Multi-Professional Training) for Wales 179 
to support sustainability.32 Annual multi-professional national meetings allowed dissemination of 180 
learning and sharing of good practice. 181 
 182 
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Data sources 184 
The Welsh Maternity Indicators Dataset (NHS Wales Informatics Service) provided data regarding 185 
number of births and mode of delivery. An all Wales OBS Cymru database was established by 186 
Improvement Cymru. Women experiencing bleeds ≥1000 mL or in whom there was concern about 187 
abnormal bleeding had a limited dataset collected. Women with bleeds ≥1500 mL or who received a 188 
transfusion had more detailed information collected (supplementary figure 2). 189 
In addition, five audits were undertaken to establish the uptake of measured blood loss and use of 190 
the paperwork proforma and the risk assessment tool. Audits included up to 30 consecutive women 191 
from each obstetric unit, irrespective of blood loss.  192 
Anonymous patient surveys were performed in 2017 (June–December) and 2018 (September). Local 193 
teams circulated forms to women experiencing PPH ≥1000mL. Questions explored communication 194 
with the mother and her family and areas for improvement in care. A staff questionnaire was 195 
circulated to local leadership teams between September and December 2018 to aid understanding 196 
of how OBS Cymru had changed local practice, to investigate which components of the intervention 197 
were thought to be important and barriers to change. 198 
 199 
Analysis 200 
Data are summarised descriptively with continuous variables reported as median, inter-quartile 201 
range (IQR) and range and categorical variables as number and percent or per 1000 maternities. 202 
Descriptive data were reported in four 6-month periods between January 2017 and December 2018 203 
to show changes across time. The intervention was being implemented during January to June 2017 204 
and this time period is compared to the last 6 month period, after the intervention had been 205 
adopted, in some analyses.  206 














Changes in the proportion of women experiencing massive PPH, the number of units of RBC 207 
transfused and intensive care admission were analysed by linear regression using the all Wales 208 
monthly data. A simple linear relationship was found to be the best model, with higher-order terms 209 
not leading to any substantial improvements in the model. The dependent variables were bleeds 210 
≥2500 mL, units of RBC transfused in Wales and episodes of intensive care and the independent 211 
variable was months in each case. Estimates are reported with 95% confidence intervals (CI). 212 
Sensitivity analyses using quasi-Poisson regression models with total maternities as offset provided 213 
very similar results. Chi square test was used to compare events in the first and last 6 month periods. 214 
Data were analysed using SPSS version 23, R version 3.6.0 and ggplot2 version 3.2.0.  215 
Role of funder 216 
The funder had no role in study design; collection, analysis, and interpretation of data; writing of the 217 




Between 1st January 2017 and 31st December 2018, 61094 women gave birth in Wales. Mode of 222 
delivery was unassisted vaginal for 62.6%, instrumental vaginal 9.5%, emergency caesarean section 223 
14.4% and non-emergency caesarean section 13.5%. There were 6024 episodes (98.6/1000 224 
maternities) recorded on the OBS Cymru database because of PPH ≥1000 mL or clinical concern of 225 
abnormal bleeding. The number of episodes increased during the project, possibly because of better 226 
recognition of total blood loss as quantitative measurement replaced visual estimation (Table 1). For 227 
PPH ≥1500 mL, 2209 episodes (36.2/1000 maternities) were reported. The mode of delivery, causes 228 
of bleeding and first recorded haemoglobin and Clauss fibrinogen remained constant throughout 229 
(Table 1).  230 
















Uptake of OBS Cymru intervention 232 
Uptake increased for all components of the OBS Cymru intervention at all sites. Uptake increased 233 
progressively across the 2 year period (Table 1 and Figure 1). Quantitative blood loss measurement 234 
increased from 83% to 98% for bleeds ≥1000 mL and Rotem analysis increased from 38% to 68% of 235 
episodes with ≥1500 mL blood loss. The proportion of women receiving treatment that was 236 
compliant with the blood component algorithm increased from 19% to 68% (Table 1). Audit data of 237 
consecutive women, irrespective of blood loss volume, showed the variation between sites in the 238 
percentage of maternities where blood loss was measured, risk assessment performed and 239 
standardised paperwork used (Figure 1). The same information, dependent on mode of delivery, is 240 
shown in supplemental figure 3.  241 
 242 
Severity of postpartum haemorrhage 243 
Incidence of massive postpartum haemorrhage 244 
Massive PPH (blood loss of 2500 mL or more) fell from 6.4 to 4.9/1000 maternities between the first 245 
and last 6 month periods (Table 2). Regression analysis suggested a progressive fall across the 24 246 
month period with an estimated decrease in massive PPH of 1.10 (95% CI 0.28 to 1.92)/1000 247 
maternities/year (P=0.011) (Fig 2a). The incidence of massive PPH at each obstetric unit during the 248 
first and last 6 months is shown in Fig 2b and 2c. These illustrate the overall decrease in massive PPH 249 
in Wales and a reduction in the number of obstetric units with massive haemorrhage rates above 250 
10/1000 maternities. More detailed obstetric unit level data are shown in supplementary material 251 
table 1. Information about the incidence of massive PPH in Wales before OBS Cymru is shown in 252 
supplementary figure 4.   253 














The all Wales incidence of PPH ≥1000 mL increased, bleeds ≥1500 remained stable and ≥2000 mL fell 254 
slightly (Table 2) throughout the 2 year period. There were progressively fewer episodes of 255 
moderate PPH (1000 mL) developing into massive haemorrhage throughout the 2 year period; in the 256 
first 6 months, 97/1386 (7.0%), second 6 months 92/1480 (6.2%), third 6 months 76/1412 (5.3%) and 257 
last 6 months, 74/1490 (5.0%) (P=0.021 comparing first and last 6 months). 258 
Intensive care admission, hysterectomy and length of hospital stay 259 
The estimated decrease in intensive care admission was 0.31 (95% CI: -0.21–0.84)/1000 260 
maternities/year (P=0.23). The total time spent in intensive care fell but this was due mainly to a 261 
prolonged stay of 168 hours for one woman in the first 6 months (Table 2). There were 22 262 
hysterectomies in total (0.36/1000 maternities), of which 19 were associated with PPH (0.31/1000) 263 
(Table 2). Of these hysterectomies, 11/19 (58%) were for placenta accreta, increta or praevia and are 264 
likely to represent appropriate care.6 7 The eight hysterectomies for PPH that were unrelated to 265 
abnormal placentation occurred at 0.13, 0.06, 0.27 and 0.07/1000 maternities in each 6 month 266 
period. These numbers are too small for meaningful comparison. The length of hospital stay for 267 
women with PPH ≥1500 mL did not change (Table 2). 268 
Transfusion of red blood cells and blood components 269 
The proportion of women transfused RBCs for PPH fell from 350/15204 (2.3%) to 268/15150 (1.8%) 270 
between the first and last 6 month periods, (P=0.0010). The total number of units of RBCs transfused 271 
in Wales fell from 54.1 to 40.2/1000 (Table 3). Regression analysis estimated that the number of 272 
units of RBCs transfused for PPH fell by 7.4 (95% CI 1.6-13.2)/1000 maternities/year, P=0.015 (Figure 273 
3a and table 3). The total number of units of RBC/1000 maternities transfused at each obstetric unit 274 
in the first and last 6 months of the project is shown in Fig 3b and 3c. The number of obstetric units 275 
that transfused ≥50 units of blood per 1000 maternities fell from 8/12 to 3/12 (P=0.041). Despite the 276 
reduction in RBC transfusions, the proportion of women with a lowest haemoglobin <80 g/L did not 277 
increase (Table 3). 278 















The proportion of women receiving FFP fell by 42% (P=0.088) and the use of fibrinogen concentrate 279 
increased by 37% (P=0.26) between the first and last 6 months (Table 3). The decrease in FFP usage 280 
occurred mainly in the final 6 months after clinicians had been encouraged to correct fibrinogen 281 
before infusing FFP.29 Infusion of cryoprecipitate and platelets was very uncommon (Table 3). 282 
Haemostatic impairment 283 
The number of laboratory coagulation tests reported increased over time and so differences 284 
between 6 month periods must be interpreted with caution. Despite this, the restrictive use of FFP 285 
was not associated with an increase in haemostatic impairment as demonstrated by the lowest 286 
fibrinogen and the longest PT/aPTT (Table 3). The median Fibtem A5 was 3 mm lower and more 287 
women had a Fibtem A5 <12 mm in the last 6 months, this is discrepant to the laboratory fibrinogen 288 
results and probably reflects the change in Fibtem A5 after the Rotem devices were updated. This 289 
may have affected the number of women receiving fibrinogen concentrate which increased in the 290 
last 6 months (Table 3).  291 
Maternal and staff feedback 292 
Eight obstetric units collected 47 patient surveys in September 2018, mean (range) blood loss 1716 293 
(1029-5743) mL. In total 66% (31/47) of women remembered being told that they were having 294 
abnormal bleeding. Of the women answering a question, 94.8% (37/39) had their questions 295 
answered fully and 100% (38/38) felt listened to by staff at the time of the event. Although 95% 296 
(39/41) felt well supported during the PPH, 29% (8/28) said that care could have been improved and 297 
better communication with mother and partner was suggested. No mother reported that the 298 
process of measuring blood loss or the escalating the multi-professional team response to her 299 
bleeding had a negative impact on the birth experience. 300 















Local leadership staff survey, response rate 29/46 (63%), reported that OBS Cymru had changed 301 
individual and unit level management of PPH. Table 4 shows the components of the intervention 302 
that clinicians thought had led to change. 303 
 304 
Discussion 305 
OBS Cymru was a national quality improvement project that aimed to reduce morbidity associated 306 
with PPH by introducing a care bundle into all 12 obstetric units in Wales. There were clinically and 307 
statistically significant reductions in massive haemorrhage across Wales with a 29% fall in the 308 
number of women progressing from moderate to massive PPH. The number of women exposed to 309 
RBC transfusion fell by 22% and the number of units of blood transfused for PPH decreased by 26%.  310 
Adoption of the whole care bundle progressively improved throughout the project with quantitative 311 
blood loss measurement approaching 100% during the last 6 months. This technique is more 312 
accurate than visual estimation, which tends to under-report actual volume, especially for large 313 
bleeds.33-38 The increase in bleeds ≥1000 mL is likely to be a consequence of relative under-reporting 314 
during the early stages of OBS Cymru when quantitative measurement was being introduced. 315 
Similarly, recognition of massive haemorrhage is likely to have improved over time and so the 316 
reduction in the rate of PPHs ≥2500 mL may be an under-estimate. 317 
The main strength of this report is that it represents service change implemented across an 318 
unselected real-world national cohort of women. It includes all women giving birth in Wales and all 319 
obstetric units irrespective of size, case mix and staffing levels. Women who gave birth in the 320 
community and experienced bleeding were transferred to an obstetric unit and are included in the 321 
results. The improvements in outcomes are internally consistent and continued throughout the 322 
project. The population, mode of delivery and cause of bleeding are similar to many high resource 323 
countries making the results widely applicable. 324 














The quality improvement methodology used means that change over time has been reported and it 325 
cannot be known for certain that the improved outcomes were the result of the care bundle. 326 
However, improvements of the size observed are very unlikely to have happened simultaneously in 327 
multiple centres by chance and progressive improvement in outcomes coincided with the 328 
progressive adoption of the intervention. The largest improvements in massive haemorrhage 329 
occurred in obstetric units with high initial rates possibly, in part, due to regression towards the 330 
mean.  331 
The blood component algorithm emphasised early treatment of hypofibrinogenaemia in line with 332 
previous studies and guidelines.5 6 12 15 18 20 39 In the last 6 month period the Rotem devices had a 333 
hardware update associated with a fall in median Fibtem. Clinicians should be wary of variations 334 
between and within point-of-care devices and engage local laboratory expertise and monitor local 335 
normal ranges.19 336 
Quantitative measurement of blood loss alone does not improve outcomes.40 However, when 337 
integrated into a care bundle such as OBS Cymru, real time accurate knowledge of blood loss acts as 338 
an enabler to prompt teams to escalate care according to guidelines.6 39 The changes in massive 339 
haemorrhage and concurrent uptake of OBS Cymru interventions suggest that measuring blood loss 340 
and using Rotem, facilitated by multi-professional team attendance at the bedside, were important 341 
factors. This was supported by feedback from clinicians, with blood loss measurement, team working 342 
and point-of-care coagulation tests stated to be the most influential changes to practice.  343 
The rate of hysterectomy for PPH remained low throughout the project (0.31/1000 maternities). 344 
Consideration of early hysterectomy in cases of abnormal placentation is advocated by guidelines 345 
and 58% of hysterectomies were reported to have abnormal placental implantation.6 7 Other studies 346 
report a hysterectomy rate of 0.6-1/1000 maternities3 21 demonstrating that hysterectomies were 347 
uncommon in Wales before OBS Cymru and this may explain why improvements were not seen.  348 














The number of women transfused RBCs for PPH fell by 22%, equivalent to about 160 women in 349 
Wales avoiding transfusion annually. RBC transfusion fell to 40 units/1000 maternities compared to 350 
a UK average of about 100 units/1000 maternities. Despite this, the lowest haemoglobin during a 351 
PPH was similar throughout the 2 year period and the proportion of women with haemoglobin 352 
below 80 g/L did not increase, suggesting the reduction in transfusion reflected reduced bleeding 353 
rather than withholding RBCs inappropriately. Treatment of antenatal anaemia was consistent 354 
throughout the project supported by the finding that the first recorded haemoglobin remained 355 
unchanged across the 2 year period.  356 
RBCs, FFP and platelets are often transfused in fixed-ratios for major PPH5 6 21 24 41-44 based on data 357 
derived from major trauma.45 46 PPH differs from major trauma because at term women have an 358 
expanded circulating blood volume and are hypercoagulable47 48 and can maintain adequate 359 
haemostasis despite moderate blood loss.15 16 Clinically significant deficiency of coagulation factors 360 
other than fibrinogen is uncommon in PPH and fixed-ratio transfusion algorithms may result in 361 
women receiving FFP with normal coagulation.17 In OBS Cymru PT/aPTT >1.5 times normal was seen 362 
in 1% of women experiencing a PPH ≥1500 mL whilst fibrinogen <2 g/L occurred in about 5%, 363 
consistent with other studies.13 15 16 In OBS Cymru Extem clot time was used to guide FFP infusion, 364 
with a 42% reduction in women receiving FFP. This occurred mainly in the last 6 months after the 365 
importance of correcting hypofibrinogenaemia before FFP administration was emphasised. During 366 
this time fewer women had PT/aPTT >1.5 times normal demonstrating that conservative use of FFP 367 
during PPH, guided by point-of-care tests, does not increase haemostatic impairment.15 368 
Other large-scale quality improvement projects for PPH have combined risk assessment, measured 369 
blood loss, standardised escalation and empirical, as opposed to targeted, blood component 370 
resuscitation.21 22 24 These initiatives have shown that, with high adoption of the interventions, 371 
severe morbidity can be reduced.21 Sites adopting The California Maternal Quality Care Collaborative 372 
care bundle reported a 21% reduction in severe maternal morbidity.24 The Association of Women's 373 














Health, Obstetric, and Neonatal Nurses PPH Project implemented a care bundle into 58 hospitals 374 
over 18 months. There was variable uptake and no statistically significant difference in maternal 375 
morbidity.22 The lack of dedicated multi-professional time was identified as a barrier. The use of 376 
multi-professional leadership teams in OBS Cymru, embedded at both a local and national level, with 377 
dedicated time to lead change, contributed to the speed, uptake and success of the project.  378 
The integrated care bundle introduced universal risk assessment to identify mothers of increased 379 
risk of PPH, whilst quantitative measurement of blood loss enabled early recognition of abnormal 380 
bleeding and progression. This facilitated escalation to more experienced midwives and obstetricians 381 
to treat the underlying cause of bleeding earlier whilst anaesthetists focused on timely resuscitation. 382 
Point-of-care tests identified cases of hypofibrinogenaemia, allowing targeted and rapid correction 383 
of coagulopathy whilst avoiding inappropriate FFP in the majority. Early identification of normal 384 
coagulation facilitated escalation of obstetric measures to control bleeding.  385 
Conclusions 386 
A care bundle for the management of PPH, that included point-of-care tests of coagulation to guide 387 
the treatment of coagulopathy, was introduced as a national quality improvement project involving 388 
more than 30000 maternities annually. Clinically significant improvements in PPH outcomes, 389 
including rates of massive haemorrhage and RBC transfusion are achievable on a national level using 390 
quality improvement methodology. Obstetric units of all size and case mix implemented and 391 
benefitted from the care bundle with improved national outcomes. These results suggest that trends 392 
towards increasing incidence of severe PPH seen over recent years can be reversed by structured 393 
multi-professional team interventions. A cluster randomised trial is needed to investigate whether 394 
the OBS Cymru care bundle improves outcomes for PPH compared to standard care.  395 
 396 
 397 
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PPH: Postpartum haemorrhage  399 
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Table 1. Demographics of women experiencing postpartum haemorrhage in Wales and uptake of the 626 









Total number of maternities in Wales 15204 15986 14754 15150 
 
Episodes with ≥1000 mL blood loss or clinical 
concern of abnormal bleeding  










Episodes with ≥1500 mL blood loss 
N (/1000 maternities) 
547 (36.0) 588 (36.8) 530 (35.9) 544 (35.9) 
Mode of delivery     
Unassisted vaginal: n (%) 211 (38.6) 228 (38.8) 203 (38.3) 184 (33.8) 
Instrumental vaginal: n (%) 115 (21.0) 116 (19.7) 123 (23.2) 147 (27.0) 
Non-emergency caesarean section: n (%) 181 (33.1) 194 (33.0) 170 (32.1) 161 (29.6) 
Emergency caesarean section: n (%) 40 (7.3) 50 (8.5) 34 (6.4) 51 (9.4) 
Not recorded: n (%) 0 (0) 0 (0) 0 (0) 1 (0.2) 
     
Cause of bleeding for episodes with ≥1500 mL 
blood loss 
N (%) 
(NB many bleeds had multiple causes) 
    
Uterine atony 323 (59.0) 352 (59.9) 276 (52.1) 315 (57.9) 
Surgery related 142 (26.0) 142 (24.1) 135 (25.5) 161 (29.6) 
Genital tract trauma 175 (32.0) 185 (31.5) 178 (33.6) 189 (34.7) 
Extragenital bleeding only 6 (1.1) 1 (0.2) 12 (2.3) 5 (0.9) 
Uterine rupture 4 (0.7) 4 (0.7) 1 (0.2) 0 (0.0) 
Placenta praevia 16 (2.9) 8 (1.4) 15 (2.8) 10 (1.8) 
Placenta accrete 5 (0.9) 7 (1.2) 5 (0.9) 5 (0.9) 
Amniotic fluid embolus 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 
Uterine inversion 1 (0.2) 1 (0.2) 0 (0.0) 1 (0.2) 
Placental abruption 17 (3.1) 14 (2.4) 17 (3.2) 23 (4.2) 
Retained products 63 (11.5) 46 (7.8) 57 (10.8) 45 (8.3) 
No cause reported 1 (0.2) 0 (0.0) 1 (0.2) 0 (0.0) 
     
First blood test after recognition of 
haemorrhage for bleeds ≥1500 mL     


















     
Uptake of OBS Cymru intervention     
Risk assessment completed. All Wales: n (% of 
all episodes ≥1000 mL)1 


















Paperwork completed. All Wales: n (% of all 
episodes ≥1000 mL)1 
 


























Blood loss quantitatively measured All Wales: n 
(% of all episodes ≥1000 mL) 
Percent blood loss measurement in individual 





















Rotem analysis performed: n (% of episodes 
with bleeds ≥1500 mL) 
Percent Rotem analyses performed  in 





















Rotem analysis requiring intervention and 
























Legend: 1One obstetric unit did not report any data for this intervention and has been excluded from 628 
the analysis and 2two obstetric units did not return Rotem data between July and December 2018. A 629 
more complete dataset was collected for episodes ≥1500 mL.  630 
 631 
 632 









Bleeds ≥1000 mL: n (/1000 maternities) 1386 (91.2) 1480 (92.6) 1412 (95.7) 1490 (98.3) 
Bleeds ≥1500 mL: n (/1000 maternities) 547 (36.0) 589 (36.8) 530 (35.9) 544 (35.9) 
Bleeds ≥2000 mL: n (/1000 maternities) 228 (15.0) 232 (14.5) 228 (15.5) 209 (13.8) 
Bleeds ≥2500 mL: n (/1000 maternities) 97 (6.4) 92 (5.8) 76 (5.2) 74 (4.9) 
Admission to intensive care for PPH: n (/1000 maternities) 10 (0.66) 12 (0.75) 9 (0.61) 6 (0.40) 
Hours in intensive care for PPH: n (/1000 maternities) 322.3 (21.2)* 290 (18.1) 180 (12.2) 124 (8.2) 
Hysterectomy associated with PPH: n (/1000 maternities) 5 (0.33) 3 (0.19) 8 (0.54) 3 (0.20) 
Length of hospital stay (days) for women with PPH ≥1500 mL: Med 














Legend: The change in number of women with moderate and severe PPH throughout the project is 635 
shown. The number of bleeds between 1000 and 1499 mL/1000 maternities was 55.2, 55.7, 59.8 and 636 
62.4 in each six month period. * one woman spent 168 hours on intensive care between January and 637 
































Table 3. Transfusion and haematological results for postpartum haemorrhage  655 
 Jan-Jun 2017 Jul-Dec 2017 Jan-Jun 2018 Jul-Dec 2018 
Transfusion of red blood cells and blood components 
Number of women transfused red blood cells: n 
(/1000 maternities) 
 
Total number of units of red blood cells transfused: 

















Number of women transfused ≥5 units red blood 
cells: n (/1000 maternities) 
16 (1.1) 14 (0.9) 14 (1.0) 11 (0.7) 
Number of women transfused FFP: n (/1000 
maternities) 
 
Total number of units of FFP transfused: 
n (/1000 maternities) 
















Number of women transfused fibrinogen: n (/1000 
maternities) 
 
Total number of grams of fibrinogen transfused: 
n (/1000 maternities) 
















Number of women transfused cryoprecipitate: n 
(/1000 maternities) 
 
Total number of units of cryoprecipitate transfused: 
n (/1000 maternities) 




















Number of women transfused platelets: n (/1000 
maternities) 
 
Total number of units of platelets transfused: 
n (/1000 maternities) 

















Lowest Clauss fibrinogen All Wales: Med (IQR), range 
 
 
Number with lowest fibrinogen ≤2 g/L n/reported 
results (% of reported results) 




















Longest PT All Wales: Med (IQR), range 
 
Number with longest PT >16 secs n/reported results 

















Longest aPTT All Wales: Med (IQR), range 
 
Number with longest aPPT >50 secs n/reported 

















Lowest Fibtem A5 All Wales: Med (IQR), range 
 
Number with lowest Fibtem A5 <12 mm n/reported 
results (% of reported results) 
















Longest Extem CT All Wales: Med (IQR), range 
 
Number with longest Extem CT >75 secs n/reported 
results (% of reported results) 
















Lowest haemoglobin All Wales: Med (IQR), range 
 
 
Number with lowest haemoglobin <80 g/L n/reported 

















Legend: * Median lowest Fibtem A5 was lower in the last 6 month period compared to the previous 656 
18 months and there were more women with Fibtem A5 <12 mm. This is likely to be due to the 657 
Rotem machine hardware update because the equivalent results for the lowest laboratory Clauss 658 
fibrinogen were similar between the first and last 6 months.  659 
 660 
 661 

















Table 4. Contribution of intervention to practice change during OBS Cymru 664 
Intervention Importance to practice 
change 
Median (IQR) 
Quantitative measurement of blood loss 5 (4-5) 
Team working 5 (3-5) 
Point-of-care testing of coagulation 5 (3-5) 
Paperwork proforma 4 (1-4) 
 665 
Legend: The importance of interventions that led to practice change were scored by OBS Cymru local 666 
champions (n=29) (1- not important, 5- most important). Responses were from 37.9% midwifery, 667 
37.9% anaesthesia, 17.2% obstetrics, 6.9% haematology. Free text responses that described how 668 
OBS Cymru had changed individual practice included ‘awareness of ongoing blood loss’, ‘proactive 669 
rather than reactive’, ‘consistent management’, ‘appropriate product administration’, 670 
‘communication and team-working’. Barriers to implementation of OBS Cymru were reported by 671 
69% (20/29) with the most common theme being reported as training in 70% (14/20). This was also 672 

































Figure  titles and legends 691 
 692 




Audits were performed at five time points throughout the quality improvement project to assess the 697 
uptake of the OBS Cymru intervention. The data indicate the percentage of cases where 698 
interventions were performed or paperwork completed in consecutive women, irrespective of blood 699 
loss. Audit data was provided by all 12 obstetric units in October 2016 (n=510), June 2017 (n=455) 700 
and June 2018 (n=492), from 11 units in December 2017 (n=405), and from seven units in December 701 
2018 (n=259). The blue, orange and pink lines refer to the rate of blood loss being quantitatively 702 
measured, paperwork proforma being present in the notes and risk assessment tool completed, 703 
respectively. Box plots with median, interquartile range and range refer to the combination of 704 
paperwork being present in the notes, the risk assessment having been completed and measured 705 
blood loss being performed. October 2016 was before OBS Cymru started and no obstetric unit had 706 
access to the paperwork or risk assessment tool, therefore, all units had zero compliance for the 707 
combined interventions at this time.  708 
 709 
 710 





















Panel A shows the monthly all Wales incidence of massive postpartum haemorrhage (≥2500 mL) 717 
with a statistically significant fall across the 24 month period. The plots show the monthly rates and 718 
for massive haemorrhage and the fitted regression line with 95% confidence interval shaded in grey. 719 
Funnel plots show the incidence of massive postpartum haemorrhages at each obstetric unit in the 720 
first (B) and last (C) 6 month periods of the quality improvement project. The line represents the 721 
mean and the limits shown are 2 and 3 standard deviations. The dashed line indicates a massive 722 
haemorrhage rate of 10/1000 maternities. The plots demonstrate the rate of massive haemorrhage 723 
at each centre during each time period, the incidence of massive postpartum haemorrhage across 724 
Wales fell from 6.4 to 4.9 per 1000 maternities and fewer units had an incidence of massive 725 
haemorrhage of more than 10/1000. The increase in massive postpartum haemorrhage reported by 726 
the smallest obstetric unit was due to two events in the final 6 months compared to one event in the 727 
























Panel A shows the monthly all Wales incidence of red blood cell (RBC) transfusion for postpartum 737 
haemorrhage during the quality improvement project. There was a statistically significant fall in the 738 
monthly rate of transfusion across the 24 months. The plot shows the monthly rates and the fitted 739 
regression line with 95% confidence interval shaded in grey. Funnel plots show the incidence of RBC 740 
transfusion for postpartum haemorrhages at each obstetric unit in the first (B) and last (C) 6 month 741 
periods of the quality improvement project. The line represents the mean and the limits shown are 2 742 
and 3 standard deviations. The dashed line represents a RBC transfusion rate of 50 units/1000 743 
maternities. These demonstrate that the total number of units of RBC transfused for postpartum 744 
haemorrhage across Wales fell from 54.1 to 40.2/1000 maternities. There was a reduction in the 745 
number of centres with RBC transfusion rate more of than 50 unit/1000 maternities between the 746 





















Supplementary material 753 
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Figure 3. Uptake of OBS Cymru interventions dependent on mode of delivery 785 
 786 
The proportion of women who had quantitatively measured blood loss (blue), paperwork proforma 787 
in the notes (orange) and risk assessment completed (pink) is shown for each of five audits 788 
dependent on mode of delivery. The box plots show median, interquartile range and range for 789 





















Change in blood loss of 2500 mL of more at individual sites 796 
Four obstetric units had a massive PPH (>2500mL) rate below 4 per 1000 maternities in the first 797 
month of 2017, all of whom observed an increase in the rate in the last 6 months of 2018. In 2 of 798 
these sites the rate remained below 4 per 1000 maternities, whilst 1 unit saw an increase to 6.0 per 799 
1000 maternities. The smallest obstetric unit in Wales reported a substantial increase in PPH rate, 800 
this was due to two events in the final 6 months compared to one event in the first 6 months and so 801 
may not be representative. This unit also reported very low use of ROTEM in cases of PPH > 1.5L PPH 802 
in comparison to the other sites. The 8 obstetric units with rates above 5 per 1000 maternities in the 803 
first 6 months of 2017 observed a reduction in massive PPH rate. In these obstetric units, completion 804 
of the paperwork in cases of PPH was the least adopted intervention, whilst risk assessment, 805 
























% of women 













of blood loss 





had a ROTEM 
test 
performed 
1418 2.6 +1.0 94.4 66.4 100 84.2 
2799 2.9 +1.0 na Na 97.6 86.2 
978 3.0 +3.0 97.3 96.4 99.1 95.7 
206 3.5 +6.2 68.0 52.0 100 18.2 
972 5.3 -4.2 97.0 95.5 98.5 na 
1947 6.0 -0.2 97.6 97.6 99.0 na 
939 7.2 -1.8 63.4 42.7 100 96.9 
1710 7.4 -3.8 60.0 32.8 99.5 69.7 
864 9.2 -6.2 88.3 53.2 97.4 88.9 
1302 10.7 -4.4 86.2 74.8 98.7 81.1 
1048 11.6 -4.0 68.4 62.4 97.4 73.3 
967 12.0 -3.7 99.1 10.1 99.1 91.2 
Legend. Table illustrating the individual obstetric unit level change in massive PPH rate and the 808 















































The trend in the incidence of bleeds ≥2500 mL before and after OBS Cymru is shown. The data 841 
between 2013 and 2016 were obtained retrospectively from obstetric units by the OBS Cymru team.  842 
There was insufficient data from two obstetric units and these were not included. An interrupted 843 
time series analysis showed an upward trend for bleeds ≥2500 mL before OBS Cymru and a 844 
downwards trend during the project. Coloured lines are for individual obstetric units and the grey 845 
line is a segmented linear mixed-effects model fitted to aggregate unit-level data with random 846 
effects for obstetric units (thus weighted by number of maternities per unit at each time point).  847 
The increase in incidence prior to the start of OBS Cymru (p=0.005) is likely to be due to the 848 
introduction of quantitative measurement of blood loss leading to improved recognition of massive 849 
haemorrhage. The retrospective data from the obstetric units and the prospective data from the 850 
OBS Cymru database cannot be directly compared because they have been collected using different 851 
methods. The comparison, however, supports the conclusion that there was a change in the trend of 852 
massive haemorrhage associated with the introduction of OBS Cymru (p=0.004).  853 
 854 
OBS Cymru 















Opinion from the lead research and development office confirming that the OBS Cymru project is a 855 
service evaluation and not research  856 
Professor Fegan was the head of the Research and Development office at the time the projected was 857 
initiated.  858 
From: Christopher Fegan (Cardiff and Vale UHB - Haematology ) 859 
Sent: 13 September 2016 16:30 860 
To: Peter Collins (Cardiff and Vale UHB - Haematology); Lee Hathaway (Cardiff and Vale UHB - 861 
Research & Development) 862 
Cc: Sarah Bell (Cardiff and Vale UHB - Anaesthetics); Peter Collins; Adam Watkins (Public Health 863 
Wales - No. 2 Capital Quarter); 'Thomas Kitchen'; Miriam John 864 
Subject: RE: Request for review of quality improvement project 865 
Dear Peter, 866 
  867 
                Both myself and Lee have reviewed this and independently come to the same conclusion 868 
that this is not research and hence does not require REC and/or R and D approval as all the 869 
parameters being collected are standard of care. I think this comes better under service 870 
evaluation/improvement. As such the permission to undertake this project resides with the 871 
individual directorates. 872 
  873 
                Thanks for sharing this with us and the best of luck. 874 
  875 
                Chris F 876 
  877 
From: Peter Collins (Cardiff and Vale UHB - Haematology) 878 
Sent: 05 September 2016 11:02 879 
To: Lee Hathaway (Cardiff and Vale UHB - Research & Development); Christopher Fegan (Cardiff and 880 
Vale UHB - Haematology ) 881 
Cc: Sarah Bell (Cardiff and Vale UHB - Anaesthetics); Peter Collins; Adam Watkins (Public Health 882 
Wales - 1000 Lives Improvement Unit); 'Thomas Kitchen'; Miriam John 883 
Subject: Request for review of quality improvement project 884 
  885 
Dear Chris 886 
  887 
Following our previous conversation I am attaching details of the Obstetric Bleeding Strategy 888 
for Wales (OBS Cymru). Our national management team does not think that this should be 889 
classified as a research project but we would like this to be formally considered by R&D. 890 
Please can you review this initiative and let us know whether you consider this to be a 891 
research study requiring ethics and R&D approval. The project has been registered in each 892 
Health Board as a Quality Improvement Project.  893 
  894 
OBS Cyrmu is a quality improvement exercise that aims to improve the management of 895 
postpartum haemorrhage throughout Wales. The initiative involves introducing a 4 stage 896 
response to postpartum haemorrhage in each of the 12 consultant-led maternity units and all 897 
midwifery-led units in Wales (see OBS Cymru 4 stage management check list). Key elements 898 
of the 4 stage response are early recognition of bleeds, measurement of blood loss, 899 
involvement of senior staff at appropriate times and point of care (Rotem and blood gas) 900 
guided blood product replacement. 901 
  902 
The introduction of the strategy will be facilitated in the units by 3 Welsh Clinical Leadership 903 
Fellows (WCLFs), a champion midwife at each unit and a lead clinician at each unit. In 904 














addition, a national midwifery project lead (22.5 hrs a week) has been funded by 1000 Lives. 905 
The project is led by a national co-ordinating team (see OBS Cymru project outline) and is 906 
supported by 1000 Lives. 907 
  908 
The project is funded by a Welsh Government grant with matched funding from TEM 909 
International (the suppliers of the Rotem machines), 1000 Lives and Welsh Deanery/Health 910 
Boards (for the WCLFs). 911 
  912 
Data will be collected on all women who have a postpartum haemorrhage >1000 mL, receive 913 
blood or blood products, have a rotem test performed, require a hysterectomy, are admitted to 914 
ITU or die. 915 
  916 
The data will be collected in an identifiable form in each maternity unit and women given a 917 
unique number. The data will be collated centrally at C&V with women identified by the 918 
unique number only. All data are routinely collected for women with postpartum 919 
haemorrhage (attached dataset). Data will be collected for 6 months before the introduction of 920 
the new management processes and for 2 ½ years after. We will look for changes in key 921 
outcomes such as ITU admission, hysterectomy, need for invasive procedures and blood 922 
product usage. There will be feedback of the results to each unit at least every 3 months to 923 
facilitate change and quality improvement. 924 
  925 
We will be interested in analysing trends across time and differences between units to 926 
identify drivers and barriers to change and quality improvement. 927 
  928 
The aggregate results will be collated, presented to stakeholders, presented at national and 929 
international meetings and submitted for publication in peer reviewed journals. Data are 930 
likely to be held at C&V for at least 2 years after completion of the project for analysis. 931 
  932 
Please let us know whether you need any further information and we would be happy to meet 933 
with you to discuss further. 934 
  935 
Best regards 936 
  937 
Peter Collins 938 
Sarah Bell 939 
Rachel Collis 940 
 941 
 942 
This preprint research paper has not been peer reviewed. Electronic copy available at: https://ssrn.com/abstract=3746928
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